VITA — Vitaminka AD Prilep Income Statement
0.000.00%
- MKD846.50m
- MKD2.40bn
- MKD3.69bn
- 48
- 88
- 78
- 87
Annual income statement for Vitaminka AD Prilep, fiscal year end - December 31st, MKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | — | IFRS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 2,351 | 2,824 | 3,812 | 3,247 | 3,689 |
Cost of Revenue | |||||
Gross Profit | 805 | 795 | 865 | 1,081 | 1,205 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 2,285 | 2,704 | 3,700 | 3,069 | 3,523 |
Operating Profit | 66.5 | 120 | 112 | 178 | 166 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 29.3 | 83.2 | 75.3 | 109 | 100 |
Provision for Income Taxes | |||||
Net Income After Taxes | 25.8 | 76.2 | 69.8 | 99.3 | 90 |
Net Income Before Extraordinary Items | |||||
Net Income | 25.8 | 76.2 | 69.8 | 99.3 | 90 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 25.8 | 76.2 | 69.8 | 99.3 | 90 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 362 | 953 | 939 | 1,267 | 1,212 |
Dividends per Share |